Senti Biosciences (SNTI) said Monday that two of three acute myeloid leukemia patients treated with its Senti-202 investigational cell therapy for relapsed or refractory hematologic malignancies, or blood cancers, achieved complete remission in a phase 1 trial.
Both patients, who were treated at the lowest dose level, showed no measurable residual disease after treatment and maintained remission for over four and three months, respectively, the company said.
The therapy was well-tolerated, with no dose-limiting toxicities reported, Senti Biosciences said. Enrolment for a dose escalation phase is ongoing, with additional data expected in 2025, Senti added.
Shares of the company soared over 141% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.